“40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"”
LLY is an industry leader with strong fundamentals; despite significant earnings growth compressing its P/E ratio, the stock remains historically expensive.
to take a look at the performance of Eli Lilly's stock over the past year. This stock has largely, and in many ways, become the benchmark for the pharmaceutical industry. Stocks rose by about 50% during this period, but have fallen by more than 10% since reaching their all-time high about a month ago.